Neuroprotective effects of an AMPA receptor antagonist YM872 in a rat transient middle cerebral artery occlusion model

Neuropharmacology

Volumn 39, Issue 2, 2000, Pages 211-217

  Kawasaki Yatsugi, Sachiko ^a   Ichiki, Chikako ^a   Yatsugi, Shin Ichi ^a   Takahashi, Masayasu ^a   Shimizu Sasamata, Masao ^a   Yamaguchi, Tokio ^a   Minematsu, Kazuo ^b  

^a Inst Drug D   (Japan)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

amino 3 hydroxy 5 methylisoxazole 4 propionate (AMPA); Focal cerebral ischemia; Receptor; YM872

Indexed keywords

[1,2,3,4 TETRAHYDRO 7 (1H IMIDAZOL 1 YL) 6 NITRO 2,3 DIOXO 1 QUINOXALINYL]ACETIC ACID; AMPA RECEPTOR; AMPA RECEPTOR ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; ISCHEMIA; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; REPERFUSION; STROKE;

ANIMALS; BRAIN ISCHEMIA; CEREBRAL ARTERIES; CEREBROVASCULAR DISORDERS; IMIDAZOLES; MALE; NEUROPROTECTIVE AGENTS; QUINOXALINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, AMPA; REPERFUSION INJURY;

EID: 0033988426     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(99)00117-3     Document Type: Article

References (26)

1. Belayev L., Alonso O.F., Bust R., Zhao W., Ginsberg M.D. Middle cerebral artery occlusion in the rat by intraluminal suture: neurological and pathological evaluation of an improved model. Stroke. 27:1996;1616-1623.
2. Buchan A.M., Gertler S.Z., Li H., Xue D., Huang Z.G., Chaundy K.E., Barnes K., Lesiuk H.J. A selective N-type Ca channel blocker prevents CA1 injury 24 h following severe forebrain ischemia and reduces infarction following focal ischemia. Journal of Cerebral Blood Flow and Metabolism. 14:1994;903-910.
3. Buchan A.M., Xue D., Huang Z.G., Smith K.H., Lesiuk H. Delayed AMPA receptor blockade reduces cerebral infarction induced by focal ischemia. NeuroReport. 2:1991;473-476.
4. Chopp M., Zhang R.L., Chen H., Li Y., Jiang N., Rusche J.R. Postischemic administration of an anti-Mac-1 antibody reduces ischemic cell damage after transient middle cerebral artery occlusion in rats. Stroke. 25:1994;869-876.
5. Garcia J.H., Wagner S., Liu K.F., Hu X. Neurological deficit and extent of neuronal necrosis attributable to middle cerebral artery occlusion in rats: statistical validation. Stroke. 26:1995;627-635.
6. Gill R. The pharmacology of α-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA)/Kainate antagonists and the role in cerebral ischaemia. Cerebrovascular Brain Metabolism Review. 6(3):1994;225-256.
7. Golanov E.V., Reis D.J. Contribution of cerebral edema to the neuronal salvage elicited by stimulation of cerebellar fastigial nucleus after occlusion of the middle cerebral artery in rat. Journal of Cerebral Blood Flow and Metabolism. 15:1995;172-177.
8. Graham S.H., Chen J., Lan J.Q., Simon R.P. A dose-response study of neuroprotection using the AMPA antagonist NBQX in rat focal cerebral ischemia. Journal of Pharmacology and Experimental Therapeutics. 276:1996;1-4.
9. Kawasaki-Yatsugi S., Yatsugi S., Takahashi M., Toya T., Ichiki C., Koshiya K., Yamaguchi T., Shimizu-Sasamata M., Minematsu K. A novel AMPA receptor antagonist, YM872, reduces infarct size after middle cerebral artery occlusion in rats. Brain Research. 793:1998;39-46.
10. Kawasaki-Yatsugi S., Shimizu-Sasamata M., Yatsugi S., Yamaguchi T. Delayed treatment with YM90K an AMPA receptor antagonist, protects ischemic damage following middle cerebral artery occlusion in rats. Journal of Pharmacy and Pharmacology. 50:1998;891-898.
11. Kohara A., Okada K., Ohno K., Sakamoto S., Shishikura J., Inami H., Shimizu-Sasamata M., Yamaguchi T. In vitro characterisation of YM872: a selective, potent and highly water-soluble AMPA receptor antagonist. Journal of Pharmacy and Pharmacology. 50:1998;795-801.
12. König J.F.R., Klippel R.A. The Rat Brain: A Stereotaxic Atlas of the Forebrain and Lower Parts of the Brain Stem. 1963;Krieger, New York.
13. Margaill I., Parmentier S., Callebert J., Allix M., Boulu R.G., Plotkine M. Short therapeutic window for MK-801 in transient focal cerebral ischemia in normotensive rats. Journal of Cerebral Blood Flow and Metabolism. 16:1996;107-113.
14. Minematsu K., Fisher M., Li L., Davis M.A., Knapp A.G., Cotter R.E., McBurney R.N., Sotak C.H. Effects of a novel NMDA antagonist on experimental stroke rapidly and quantitatively assessed by diffusion-weighted MRI. Neurology. 43:1993;397-403.
15. Minematsu K., Fisher M., Li L., Sotak C.H. Diffusion and perfusion magnetic resonance imagine studies to evaluate a noncompetitive N-methyl-D-aspartate antagonist and reperfusion in experimental stroke in rats. Stroke. 24:1993;2074-2081.
16. Nagasawa H., Kogure K. Exo-focal postischemic neuronal death in the rat brain. Brain Research. 524:1990;196-202.
17. Sheardown M.J., Nielsen E.Ø., Hansen A.J., Jacobsen P., Honore T. 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F)-quinoxaline: a neuroprotectant for cerebral ischemia. Science. 247:1990;571-574.
18. Shimizu-Sasamata M., Kawasaki-Yatsugi S., Okada M., Sakamoto S., Yatsugi S., Togami J., Hatanaka K., Ohmori J., Koshiya K., Usuda S., Murase K. YM90K: Pharmacological characterization as a selective and potent α-amino-3,5-methylisoxazole-4-propionate (AMPA)/Kainate receptor antagonist. Journal of Pharmacology and Experimental Therapeutics. 276:1996;84-92.
19. Shimizu-Sasamata M., Kano T., Rogowska J., Wolf G.L., Moskowitz M.A., Lo E.H. YM872, a highly water soluble AMPA receptor antagonist, preserves the hemodynamic penumbra and reduces brain injury after permanent focal ischemia in rats. Stroke. 29:1998;2141-2148.
20. Small D.L., Murray C.L., Monette R., Kawasaki-Yatsugi S., Morley P. Neuroprotective effects of a novel AMPA receptor antagonist, YM872. NeuroReport. 7:1998;43-46.
21. Smith S.E., Merdrum B.J. Cerebroprotective effect of a non-N-methyl-D-aspartate antagonist, GYKI52466, after focal ischaemia in the rat. Stroke. 23:1992;861-864.
22. Takahashi M., Ni J.W., Kawasaki-Yatsugi S., Toya T., Yatsugi S., Shimizu-Sasamata M., Koshiya K., Shishikura J., Sakamoto S., Yamaguchi T. YM872, a novel selective α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist, reduces brain damage after permanent focal ischemia in cats. Journal of Pharmacology and Experimental Therapeutics. 284:1998;467-473.
23. Umemura K., Shimakura A., Nakashima M. Neuroprotective effect of a novel AMPA antagonist, YM90K in rat focal cerebral ischemia. Brain Research. 773:1997;61-65.
24. Valentino K., Newcomb R., Gadbois T., Singh T., Bowersox S., Bitner S., Justice A., Yamashiro D., Hoffmann B.B., Ciaranello R., Miljanich G., Ramachandran J. A selective N-type calcium channel antagonist protects against neuronal loss after global cerebral ischemia. Proceedings of the National Acadamy of Sciences USA. 90:1993;7894-7897.
25. Xue D., Huang Z.G., Barnes K., Lesiuk H.J., Smith K.E., Buchan A.M. Delayed treatment with AMPA, but not NMDA, antagonists reduces neocortical infarction. Journal of Cerebral Blood Flow and Metabolism. 14:1994;251-261.
26. Longa E.Z., Weinstein P.R., Carlson S., Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 20:1989;84-91.